Artists with ME/CFS/FM/SEID Online Juried Art Exhibition

May 16, 2015

Author:

#MEAction

M.E. AGAIN – Art Exhibition

M.E. AGAIN is an online juried art showcase for those with myalgic encephalomyelitis, fibromyalgia, chronic fatigue syndrome, systemic exertion intolerance disease. Selected artists each have their own page with their art, artist information and experience of and with chronic illness. This artist showcase will remain up from May 12th, 2015 to May 12th, 2016.

[button_color url=”http://www.meagain.org” content=”View the Exhibition” target=””] Please go to www.meagain.org for more information. Artwork titled “21 Years Undiagnosed Lyme” by Ms. Erin Fromkes ©2014

Categories: Actions, Arts & Letters, Awareness, Events, Featured events, Global
Tags: art, artists, awareness

1 thought on “Artists with ME/CFS/FM/SEID Online Juried Art Exhibition”

Donia
December 24, 2015 at 11:36 am

What a fantastic idea. I’d love to participate in future exhibitions… this particular series of my work concerning my chronic pain and illnesses never gets to see the light of day!

Comments are closed.

Latest News

Urgent Action Needed: Demand NIH Fund the ME/CFS Research Roadmap!

October 10, 2024 No Comments

Submit Long COVID Drug Recommendations to RECOVER-TLC!

October 7, 2024 No Comments

Last month, RECOVER TLC met at NIH headquarters in Bethesda. The goal was to initiate a drug development strategy for Long COVID clinical trials. Now, RECOVER TLC has opened the RECOVER-TLC Intervention Information Request Form, where you can make suggestions about which drugs and other interventions to trial! Anyone can submit a therapeutic for consideration

A classroom of people watching a panel discussion.

The RECOVER-Treating Long COVID (RECOVER TLC) The Path Forward

September 26, 2024 No Comments

The RECOVER-Treating Long COVID (RECOVER TLC) Kick-off Meeting was Sept 23-25 in person and over Zoom. I had the privilege of attending over Zoom and Jaime Seltzer, #MEAction’s Scientific Director, represented the needs of the ME community in person and as an invited member of a panel on clinical trial design. There were many speakers